Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.56 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21636412 | 0.95 | HTR6 (0.49) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL23252291 | 0.82 | HTR6 (0.36) | HTR6JAK2BTKBCHECYP3A4 | |
| SCHEMBL17394178 | 0.82 | HTR6 (0.51) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL29967700 | 0.82 | HTR6 (0.51) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL21636425 | 0.80 | HTR6 (0.41) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL21636626 | 0.79 | HTR6 (0.36) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL16916841 | 0.79 | PIK3C3 (0.45) | HTR6PIK3C3 | |
| SCHEMBL21636885 | 0.78 | HTR6 (0.38) | HTR6JAK2BTKCYP3A4CYP2D6 | |
| SCHEMBL4601850 | 0.78 | HTR6 (0.54) | HTR6CYP3A4CYP2D6HTR1ADRD2 | |
| SCHEMBL21624158 | 0.78 | PIK3C3 (0.38) | HTR6JAK2BTKPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünethal GmbH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | HTR6 587/4885JAK2 2093/4885BTK 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.